The FDA approved 46 new drugs last year, the highest total in more than two decades.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
An overview of kinase downregulators and recent advances in discovery approaches
Signal Transduction and Targeted Therapy Open Access 20 December 2021
Access options
Change history
01 February 2018
Semaglutide is the sixth GLP1 agonist to receive FDA approval, not the fifth as originally noted. This correction has been made in the print and online versions.
Rights and permissions
About this article
Cite this article
Mullard, A. 2017 FDA drug approvals. Nat Rev Drug Discov 17, 81–85 (2018). https://doi.org/10.1038/nrd.2018.4
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2018.4
This article is cited by
-
Artificial viruses: A nanotechnology based approach
DARU Journal of Pharmaceutical Sciences (2023)
-
Synthesis and dopamine receptor binding of dihydrexidine and SKF 38393 catecholamine-based analogues
Amino Acids (2022)
-
Trends in PhysChem Properties of Newly Approved Drugs over the Last Six Years; Predicting Solubility of Drugs Approved in 2021
Journal of Solution Chemistry (2022)
-
Predicting Solubility of Newly-Approved Drugs (2016–2020) with a Simple ABSOLV and GSE(Flexible-Acceptor) Consensus Model Outperforming Random Forest Regression
Journal of Solution Chemistry (2022)
-
An overview of kinase downregulators and recent advances in discovery approaches
Signal Transduction and Targeted Therapy (2021)